Compare Mesoblast Limited (MESO) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Mesoblast Limited trades at $16.73 (market cap $2.20B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $10.8. The key difference: Mesoblast Limited is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| MESO | MSTZ | |
|---|---|---|
Market Cap | $2.20B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $20.96 | $27.92 |
52-Week Low | $12.88 | $3.94 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.
Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.
MSTZ stock trades at $11.40, showing a 5.36% daily gain amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, while oscillators remain neutral. Financial ratios including P/E, P/S, and P/B are unavailable in current data. Recent ETF performance news indirectly references momentum names but lacks direct MSTZ coverage.
The outlook remains cautious with technical indicators favoring bearish momentum. Investment opportunity hinges on fundamental improvements currently obscured by missing financial data. Key risks include continued technical weakness and lack of clear fundamental catalysts. Investors should await earnings clarity for directional conviction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
